Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

According to this review, frontal fibrosing alopecia in men exhibits unique clinical features and is often misdiagnosed, underscoring the need for validated diagnostic criteria and treatment evaluation.

This study found that fibroblasts from Emery-Dreifuss muscular dystrophy patients with certain genetic mutations overexpress markers of fibrosis, and gene correction techniques reduced fibrogenic molecule expression in cell models, suggesting potential therapeutic applications.

This study found that among women with frontal fibrosing alopecia, 100% showed dermoscopic elements suggestive of the condition, with perifollicular erythema often indicating disease activity.

This case report describes three pediatric cases of frontal fibrosing alopecia, a condition typically seen in postmenopausal women, including a unique instance involving female twins.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This case-control study found that men with earlier onset androgenetic alopecia, particularly frontal balding, may have an increased risk of prostate cancer in a multiethnic veterans cohort.

This study found that low-level laser therapy effectively reduced relapse rates, while functional appliances did not; combining them offered no additional benefits.

This review suggests that annurca apple extract, rich in polyphenols, may be a promising alternative for treating baldness, though further research is needed to clearly assess its effectiveness compared to existing treatments.

In this study, FCO2 laser treatment showed significantly better improvement for alopecia areata compared to traditional intralesional corticosteroid injections, with no serious side effects or relapse observed.

This article reviews the use of tofacitinib for rheumatoid and psoriatic arthritis and alopecia areata, noting potential serious side effects, but reports no cases of palmoplantar pustulosis from the therapy.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

In this study, ethyl acetate fraction of Eclipta alba was found to inhibit adipogenesis and reduce dyslipidemia in hamsters, suggesting potential as an herbal treatment for obesity.

This study found that the protein Formin 2 helps regulate cell-to-cell transport in thale cress by stabilizing actin filaments at plasmodesmata, with its absence leading to increased permeability and vulnerability to viral infections.

This study suggests that supplementing with a cell-free fat extract might enhance embryo development and improve clinical outcomes in older women experiencing in vitro fertilization failure.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This case report describes a patient with a severe pruritic rash and hair loss in both axillary regions, with no fluorescence under a Wood's lamp and hair follicle-centred papules observed through dermoscopy.

This study found that pediatric alopecia areata patients with atopic predisposition showed heightened immune and inflammatory responses, including significant immune cell infiltration, compared to adults and healthy controls.

This study found that epidermal growth factor may stimulate the growth of hair follicle epithelium and potentially accelerate the transition from anagen to catagen phase in cultured human hair follicles.

This paper reviews the autoimmune disorder alopecia areata, its progression, and its significant emotional and psychological impact, but reports no new clinical findings.

This case report describes three instances of eosinophilic pustular folliculitis lacking visible pustules, which histopathology confirmed involve eosinophilic infiltration around hair follicles.

This study found that P144 (Disitertide) significantly reduced collagen deposition and improved muscle organization in a rabbit model of post-radiotherapy fibrosis, suggesting potential antifibrotic effects.

In this study, DanEra, an herbal hair tonic from Pomegranate and Beetroot extracts, showed equivalent effectiveness to the standard drug Ketoconazole in microbiological tests and provided significant relief from severe dandruff in all volunteers within 10 days.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.